The procedure is based on chimeric monoclonal antibodies where variable regions are derived from newly infected macaque lymphocytes. The procedure was succesfully tested with H5N1 avian flue virus subtypes.
Weixu MENG et al., PLoS ONE June 8 (6) : e66276